BioNTech’s Tumultuous Transition: From Vaccine Giant to Cancer Therapy Pioneer
BioNTech's transition involves a shift from COVID-19 vaccine dependency to pioneering mRNA-based cancer therapies. Despite a notable profit decline, BioNTech exceeded market expectations, recording an EPS of €1.08 against the…